2024
Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome
Tantry U, Raghavakurup L, Becker R, Singh S, Bliden K, Gurbel P. Milvexian: evaluating the factor XIa inhibitor for the treatment of acute coronary syndrome. Expert Opinion On Pharmacotherapy 2024, 25: 1271-1280. PMID: 39072402, DOI: 10.1080/14656566.2024.2385062.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeCoronary syndromeElevated risk of bleedingPathological thrombosisTreatment of acute coronary syndromesClinical thrombotic eventsPhysiological hemostasisRisk of bleedingPrevention of thrombosisFXIa inhibitorsBleeding riskReceptor blockersThrombotic eventsAntiplatelet therapyPlatelet antagonistsAntithrombotic efficacyFXIa inhibitionThrombosisExperimental thrombosisPatientsElevated riskLiterature searchAnticoagulationLarge-scale studiesFXIa
2023
Evaluating chest pain in patients with post COVID conditions permission to think outside of the box
Becker R. Evaluating chest pain in patients with post COVID conditions permission to think outside of the box. Journal Of Thrombosis And Thrombolysis 2023, 55: 592-603. PMID: 37052772, PMCID: PMC10098243, DOI: 10.1007/s11239-023-02808-8.Peer-Reviewed Original Research